XTL Biopharmaceuticals
XTLB
6 hedge funds and large institutions have $175K invested in XTL Biopharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.1% less ownership
Funds ownership: 0.87% → 0.77% (-0.1%)
8% less capital invested
Capital invested by funds: $191K → $175K (-$15.5K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SP
SmartHarvest Portfolios
Poulsbo,
Washington
|
+$42.3K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$774 |
| 3 |
GI
GAMMA Investing
Foster City,
California
|
+$526 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$44K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$5.94K |
| 3 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$4.88K |
| 4 |
Morgan Stanley
New York
|
-$1.35K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NI
1
Noked Israel
Ramat Hasharon,
Israel
| $120K | – | – | – |
|
|
SP
2
SmartHarvest Portfolios
Poulsbo,
Washington
| $32.2K | +$42.3K | +13,351 | New |
|
|
3
RhumbLine Advisers
Boston,
Massachusetts
| $14.4K | -$4.88K | -1,540 | -20% |
|
|
GI
4
GAMMA Investing
Foster City,
California
| $8.16K | +$526 | +166 | +5% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $588 | +$774 | +244 | New |
|
|
6
Morgan Stanley
New York
| $24 | -$1.35K | -425 | -98% |
|
|
7
Citadel Advisors
Miami,
Florida
| – | -$44K | -18,967 | Closed |
|
|
XT
8
XTX Topco
George Town,
Cayman Islands
| – | -$5.94K | -2,560 | Closed |
|
XTLB Hedge Fund Activity: Q1 2026 in Review
6 of the 8,142 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q1 2026, worth a combined $175K — down 8.1% from $191K a quarter earlier.
Fund positioning in XTLB was balanced in Q1 2026: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was SmartHarvest Portfolios, opening a new position worth an estimated $42.3K. The largest seller was Citadel Advisors, exiting entirely with an estimated $44K sold.
- 6 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $175K of XTL Biopharmaceuticals stock for Q1 2026, down 8.1% quarter-over-quarter.
- 2 funds opened new XTL Biopharmaceuticals positions in Q1 2026 and 2 closed out, a net change of 0 holders.
- The largest XTL Biopharmaceuticals buyer in Q1 2026 was SmartHarvest Portfolios, an estimated $42.3K added.
- The largest XTL Biopharmaceuticals seller in Q1 2026 was Citadel Advisors, an estimated $44K sold.
Based on aggregated 13F filings for Q1 2026.